As of July 2026, according to Exelixis's latest financial report, the company's current EPS (TTM) is $3.12. In 2025, the company recorded an earnings per share (EPS) of $2.88, which represents an increase compared to its EPS of $1.8 in 2024. Exelixis's earnings per share for the quarterly report ending on Mar 31, 2026 was $0.81.
The annual EPS in 2025 was $2.88, an increase of 60% from $1.8 in 2024. For the quarter ending Mar 31, 2026, the EPS was $0.81, showing a 42.1% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $3.12. In 2024, the annual EPS was $1.8, showing an increase of 176.9% from 2023.
Over the last 12 months, Exelixis has registered an EPS growth of 42.1% (YoY, quarterly). Over a three-year span, the company had an average EPS growth of 71.6% per year. Over the last 5 years, the company had an average EPS growth rate of 51.6%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| BMY Bristol Myers Squibb Co | 16.28 | 178.7% | 5.3% | N/A |
| EXEL Exelixis Inc | 17.9 | 60% | 71.6% | 51.6% |
| PFE Pfizer Inc | 18.56 | -3.5% | -37.4% | -3.7% |
| AMGN Amgen Inc | 25.84 | 88.1% | 5.6% | 2.9% |
| JNJ Johnson & Johnson | 30.13 | 90.6% | 17.7% | 14.8% |
| MRK Merck & Co Inc | 36.29 | 8% | 8.4% | 21.2% |
| CRIS Curis Inc | N/A | 91.6% | N/A | N/A |
All data is based on quarterly TTM periods, unless otherwise specified.